Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, and Semaglutide, a GLP-1 RA, have shown greater weight loss efficacy than traditional medications like Phentermine/Topiramate (Qsymia), Naltrexone/Bupropion (Contrave), and Phentermine 12,14,15
Our team of licensed U.S
ParadaVenegas D
CEO Brian Lian said on the companys recent earnings call that early testing suggested the compound compared favorably with Novo Nordisks amylin candidate: When we looked at data in rodents, it seemed to be better than Cagrilintide. He also noted stronger signals relative to Vikings own lead obesity therapy in animal testing, saying, When we looked in obese monkeys, it seemed to provide better weight loss than VK2735. it was very potent on the receptors, very good PK [pharmacokinetics] profile that would be amenable to weekly dosing, we think, and that marries up nicely with the 2735-PK profile. The company recently filed an investigational new drug application for VK3019 and expects to begin Phase 1 testing this quarter
Unknown Ingredients: Patches made from supplements might have unsafe or hidden additives
This means they should only be accessed through a qualified health professional for a legitimate medical indication
